Image de couverture de livre

An orthotopic prostate cancer model for new treatment development using syngeneic or patient‐derived tumors

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Naz Chaudary, E. Wiljer, Warren Foltz, Pratibha Thapa, Richard P. Hill, Michael Milosevic
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	The Prostate
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer
par: Catherine H. Marshall, et autres
Publié: (2024)

Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy
par: Fabio Matrone, et autres
Publié: (2024)

Bellmunt risk score as a survival predictor in patients with metastatic castration‐resistant prostate cancer
par: Thomas Büttner, et autres
Publié: (2024)

Consistent predictive ability of prostate‐specific antigen density prediction model for clinically significant prostate cancer across age strata
par: Kamil Malshy, et autres
Publié: (2024)

Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix
par: Shuhei Kamada, et autres
Publié: (2024)

Does larger prostate size provide protection for cancer specific outcomes in localized prostate cancer
par: Zain Abedali, et autres
Publié: (2024)

Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate
par: Eric V. Li, et autres
Publié: (2024)

Diagnosis and management of neuroendocrine prostate cancer
par: Ivan de Kouchkovsky, et autres
Publié: (2024)

Differences in real‐world outcomes by risk classification for localized prostate cancer patients after radiation therapy
par: Lawrence Karsh, et autres
Publié: (2024)

Impact of presentation timing in metastatic hormone‐sensitive prostate cancer: Characterization of patients and identification of prognostic factors
par: Juliana Arenas Hoyos, et autres
Publié: (2024)

Predicting clinically significant prostate cancer in elderly patients: A nomogram approach with shear wave elastography
par: Xiang Liu, et autres
Publié: (2024)

Other‐cause mortality in incidental prostate cancer
par: Francesco Di Bello, et autres
Publié: (2024)

Influence of microbiome in intraprostatic inflammation and prostate cancer
par: Pranav Prakash, et autres
Publié: (2024)

The effect of dose‐escalation radiotherapy with simultaneous‐integrated‐boost on the use of short‐term androgen deprivation therapy in patients with intermediate risk prostate cancer
par: Cem Onal, et autres
Publié: (2024)

Deep PSA response and extended time‐to‐nadir as robust predictors of survival in Asian patients with de novo metastatic hormone‐sensitive prostate cancer receiving upfront intensified treatment
par: Chris H.‐M. Wong, et autres
Publié: (2024)

Impact of definitive radiotherapy on metabolic response measured with 68Ga‐PSMA‐PET/CT in patients with intermediate‐risk prostate cancer
par: Cem Onal, et autres
Publié: (2024)

Assessing state‐of‐the‐art online large language models for patient education regarding prostatitis
par: Pengfei Zhang, et autres
Publié: (2024)

The detection rate for prostate cancer in systematic and targeted prostate biopsy in biopsy‐naive patients, according to the localization of the lesion at the mpMRI: A single‐center retrospective observational study
par: Matteo Massanova, et autres
Publié: (2024)

Cutibacterium acnes invades prostate epithelial cells to induce BRCAness as a possible pathogen of prostate cancer
par: Shingo Ashida, et autres
Publié: (2024)

Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients
par: Tokiyoshi Tanegashima, et autres
Publié: (2024)

Cumulative cancer locations on prostate biopsy and active surveillance outcomes in the MRI era
par: Sean A. Fletcher, et autres
Publié: (2024)

FOXA1 regulates ribosomal RNA transcription in prostate cancer
par: Tianwei Jia, et autres
Publié: (2024)

Translation and validation of a lifestyle questionnaire related to prostate cancer
par: Reyhane Karegar‐Niavol, et autres
Publié: (2024)

Real‐world prevalence of adverse events with first‐line systemic therapies among patients with metastatic castration‐sensitive prostate cancer
par: Umang Swami, et autres
Publié: (2024)

Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open‐label, phase 2 trial
par: Albertas Ulys, et autres
Publié: (2024)

Targeting proliferating cell nuclear antigen enhances ionizing radiation‐induced cytotoxicity in prostate cancer cells
par: Shan Lu, et autres
Publié: (2024)

Prognostic model for second progression‐free survival and overall survival in patients with high‐risk metastatic hormone‐sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy
par: Shintaro Narita, et autres
Publié: (2024)

The predictive impact of hematological inflammatory markers in detecting prostate cancer in patients with PI‐RADS 3 lesions on multiparametric magnetic resonance imaging
par: Ridvan Kayar, et autres
Publié: (2024)

Reply to Letter to the Editor on “Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients”
par: Tokiyoshi Tanegashima, et autres
Publié: (2024)

Size and SUVmax define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer
par: Fabian Falkenbach, et autres
Publié: (2024)

Lower urinary tract symptoms in elderly men: Considerations for prostate cancer testing
par: Stephen Schmit, et autres
Publié: (2024)

L1CAM mediates neuroendocrine phenotype acquisition in prostate cancer cells
par: Chia‐Ling Hsieh, et autres
Publié: (2024)

Development and validation of an imageless machine‐learning algorithm for the initial screening of prostate cancer
par: Nicolas Martelin, et autres
Publié: (2024)

PIK3/Akt/mTOR pathway alterations in metastatic castration‐sensitive prostate cancer
par: Philip Sutera, et autres
Publié: (2024)

VOC‐based detection of prostate cancer using an electronic nose and ion mobility spectrometry: A novel urine‐based approach
par: Hendrik Heers, et autres
Publié: (2024)

Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real‐world setting of metastatic hormone‐sensitive prostate cancer patients
par: Mike Wenzel, et autres
Publié: (2024)

Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome
par: Eli Marie Grindedal, et autres
Publié: (2024)

External validation of the Memorial Sloan Kettering Cancer Center preoperative nomogram predicting lymph node invasion in a cohort of high‐grade prostate cancer patients
par: Nawar Touma, et autres
Publié: (2024)

The role of gut microbiota involved in prostate microenvironment and symptoms improvement in chronic prostatitis/chronic pelvic pain syndrome patients treated with low‐intensity extracorporeal shock wave
par: Xiangbin Kong, et autres
Publié: (2024)

Real‐world study: Impact of multidisciplinary management of apalutamide‐associated adverse events in prostate cancer
par: Julián Córdoba Sánchez, et autres
Publié: (2024)